SERINC3

Summary

SERINC3 (serine incorporator 3, HGNC:11699) is a protein-coding gene on chromosome 20q13.12, encoding Serine incorporator 3 (Q13530). Restriction factor required to restrict infectivity of lentiviruses, such as HIV-1: acts by inhibiting an early step of viral infection.

Enables phospholipid scramblase activity. Involved in antiviral innate immune response and plasma membrane phospholipid scrambling. Located in plasma membrane.

Source: NCBI Gene 10955 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 90 total
• MANE Select transcript: NM_006811

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11699
Approved symbol	SERINC3
Name	serine incorporator 3
Location	20q13.12
Locus type	gene with protein product
Status	Approved
Aliases	DIFF33, TDE, SBBI99, TMS-1, AIGP1
Ensembl gene	ENSG00000132824
Ensembl biotype	protein_coding
OMIM	607165
Entrez	10955

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 16 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000255175, ENST00000342374, ENST00000411544, ENST00000468234, ENST00000885443, ENST00000885444, ENST00000885445, ENST00000885446, ENST00000885447, ENST00000885448, ENST00000885449, ENST00000885450, ENST00000930100, ENST00000930101, ENST00000967986, ENST00000967987, ENST00000967988

RefSeq mRNA: 2 — MANE Select: NM_006811 NM_006811, NM_198941

CCDS: CCDS13333

Canonical transcript exons

ENST00000342374 — 10 exons

Exon	Start	End
ENSE00000906879	44501073	44501300
ENSE00000906880	44503815	44503995
ENSE00000906881	44504801	44504891
ENSE00000906882	44506827	44506996
ENSE00000906883	44509891	44510028
ENSE00000906884	44511289	44511368
ENSE00000906885	44512801	44512994
ENSE00001390812	44497441	44500434
ENSE00001878341	44521913	44522070
ENSE00003614266	44513879	44514040

Expression profiles

Bgee: expression breadth ubiquitous, 304 present calls, max score 98.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 100.1554 / max 1086.0779, expressed in 1822 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187347	99.9815	1822
187345	0.0968	36
187346	0.0770	31

Top tissues by expression

304 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	98.84	gold quality
tendon of biceps brachii	UBERON:0008188	98.81	gold quality
pons	UBERON:0000988	98.47	gold quality
medial globus pallidus	UBERON:0002477	98.24	gold quality
Brodmann (1909) area 23	UBERON:0013554	98.23	gold quality
middle temporal gyrus	UBERON:0002771	98.17	gold quality
tendon	UBERON:0000043	98.09	gold quality
superior frontal gyrus	UBERON:0002661	98.04	gold quality
stromal cell of endometrium	CL:0002255	98.02	gold quality
globus pallidus	UBERON:0001875	97.94	gold quality
postcentral gyrus	UBERON:0002581	97.83	gold quality
prefrontal cortex	UBERON:0000451	97.82	gold quality
orbitofrontal cortex	UBERON:0004167	97.81	gold quality
Brodmann (1909) area 46	UBERON:0006483	97.81	gold quality
parietal lobe	UBERON:0001872	97.80	gold quality
superior vestibular nucleus	UBERON:0007227	97.79	gold quality
trigeminal ganglion	UBERON:0001675	97.75	gold quality
calcaneal tendon	UBERON:0003701	97.69	gold quality
right testis	UBERON:0004534	97.64	gold quality
left testis	UBERON:0004533	97.62	gold quality
adult organism	UBERON:0007023	97.59	gold quality
islet of Langerhans	UBERON:0000006	97.55	gold quality
inferior vagus X ganglion	UBERON:0005363	97.50	gold quality
dorsal root ganglion	UBERON:0000044	97.49	gold quality
placenta	UBERON:0001987	97.42	gold quality
entorhinal cortex	UBERON:0002728	97.42	gold quality
vena cava	UBERON:0004087	97.42	gold quality
cauda epididymis	UBERON:0004360	97.36	gold quality
subthalamic nucleus	UBERON:0001906	97.33	gold quality
occipital lobe	UBERON:0002021	97.32	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	11.73
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GABPA

miRNA regulators (miRDB)

135 targeting SERINC3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-548J-3P	99.94	72.61	4881

Literature-anchored findings (GeneRIF, showing 4)

• TDE1 inhibits apoptosis and stimulates tumorigenesis (PMID:16547497)
• SERINC3 and SERINC5 together restricted HIV-1 replication, and this restriction was evaded by Nef (PMID:26416733)
• In MOLT-3 cells, Nef remained crucial for HIV-1 replication even in the absence of SERINC3 and SERINC5. (PMID:31186327)
• HIV-cell membrane fusion intermediates are restricted by Serincs as revealed by cryo-electron and TIRF microscopy. (PMID:32788212)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	SERINC3	ENSDARG00000086133
danio_rerio	si:ch73-267c23.10	ENSDARG00000111669
mus_musculus	Serinc3	ENSMUSG00000017707
rattus_norvegicus	Serinc3	ENSRNOG00000009552
drosophila_melanogaster	Serinc	FBGN0028399
caenorhabditis_elegans		WBGENE00011250
caenorhabditis_elegans		WBGENE00021956

Paralogs (4): SERINC1 (ENSG00000111897), SERINC5 (ENSG00000164300), SERINC2 (ENSG00000168528), SERINC4 (ENSG00000184716)

Protein

Protein identifiers

Serine incorporator 3 — Q13530 (reviewed: Q13530)

Alternative names: Tumor differentially expressed protein 1

All UniProt accessions (2): Q13530, Q5H936

UniProt curated annotations — full annotation on UniProt →

Function. Restriction factor required to restrict infectivity of lentiviruses, such as HIV-1: acts by inhibiting an early step of viral infection. Impairs the penetration of the viral particle into the cytoplasm. Non-ATP-dependent, non-specific lipid transporter for phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. Functions as a scramblase that flips lipids in both directions across the membrane. Phospholipid scrambling results in HIV-1 surface exposure of phosphatidylserine and loss of membrane asymmetry, which leads to changes in HIV-1 Env conformation and loss of infectivity.

Subcellular location. Cell membrane. Golgi apparatus membrane Cytoplasm. Perinuclear region.

Tissue specificity. Ubiquitous. Expression levels were increased fourfold to tenfold in lung tumor tissues compared with normal pulmonary tissues.

Post-translational modifications. N-glycosylated.

Similarity. Belongs to the TDE1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q13530-1	1	yes
Q13530-2	2

RefSeq proteins (2): NP_006802, NP_945179 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005016	TDE1/TMS	Family

Pfam: PF03348

Catalyzed reactions (Rhea), 3 shown:

• a 1,2-diacyl-sn-glycero-3-phosphocholine(in) = a 1,2-diacyl-sn-glycero-3-phosphocholine(out) (RHEA:38571)
• a 1,2-diacyl-sn-glycero-3-phospho-L-serine(in) = a 1,2-diacyl-sn-glycero-3-phospho-L-serine(out) (RHEA:38663)
• a 1,2-diacyl-sn-glycero-3-phosphoethanolamine(in) = a 1,2-diacyl-sn-glycero-3-phosphoethanolamine(out) (RHEA:38895)

UniProt features (22 total): topological domain 9, transmembrane region 8, chain 1, modified residue 1, glycosylation site 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7RU6	ELECTRON MICROSCOPY	4.4
7RUG	ELECTRON MICROSCOPY	4.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13530-F1	77.55	0.45

Antibody-complex structures (SAbDab): 2 — 7RU6, 7RUG

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 371

Glycosylation sites (1): 34

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-977347	Serine metabolism
R-HSA-1430728	Metabolism
R-HSA-71291	Metabolism of amino acids and derivatives

MSigDB gene sets: 305 (showing top): MULLIGHAN_NPM1_SIGNATURE_3_UP, FREAC2_01, GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_PLASMA_MEMBRANE_ORGANIZATION, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP, GOLDRATH_ANTIGEN_RESPONSE, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, MARTINEZ_RB1_TARGETS_UP, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_APOPTOTIC_SIGNALING_PATHWAY, GOBP_REGULATION_OF_ENDOPLASMIC_RETICULUM_STRESS_INDUCED_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY

GO Biological Process (9): L-serine metabolic process (GO:0006563), plasma membrane phospholipid scrambling (GO:0017121), antiviral innate immune response (GO:0140374), positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway (GO:1902237), immune system process (GO:0002376), L-serine biosynthetic process (GO:0006564), L-serine transport (GO:0015825), innate immune response (GO:0045087), defense response to virus (GO:0051607)

GO Molecular Function (4): phospholipid scramblase activity (GO:0017128), molecular carrier activity (GO:0140104), protein binding (GO:0005515), L-serine transmembrane transporter activity (GO:0015194)

GO Cellular Component (6): Golgi membrane (GO:0000139), plasma membrane (GO:0005886), membrane (GO:0016020), perinuclear region of cytoplasm (GO:0048471), cytoplasm (GO:0005737), Golgi apparatus (GO:0005794)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Metabolism of amino acids and derivatives	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
binding	2
cytoplasm	2
L-amino acid metabolic process	1
proteinogenic amino acid metabolic process	1
plasma membrane organization	1
phospholipid translocation	1
innate immune response	1
defense response to virus	1
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	1
regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	1
positive regulation of response to endoplasmic reticulum stress	1
positive regulation of intrinsic apoptotic signaling pathway	1
biological_process	1
L-serine metabolic process	1
serine family amino acid biosynthetic process	1
L-amino acid biosynthetic process	1
proteinogenic amino acid biosynthetic process	1
L-amino acid transport	1
serine transport	1
immune response	1
defense response to symbiont	1
defense response	1
response to virus	1
plasma membrane phospholipid scrambling	1
intramembrane lipid carrier activity	1
molecular_function	1
L-amino acid transmembrane transporter activity	1
L-serine transport	1
Golgi apparatus	1
bounding membrane of organelle	1
membrane	1
cell periphery	1
intracellular anatomical structure	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

794 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SERINC3	GRXCR1	A8MXD5	892
SERINC3	BST2	Q10589	591
SERINC3	SAMHD1	Q9Y3Z3	578
SERINC3	RUSC2	Q8N2Y8	572
SERINC3	TRIM5	Q9C035	554
SERINC3	GLRX	P35754	548
SERINC3	MARCHF2	Q9P0N8	524
SERINC3	RUSC1	Q9BVN2	516
SERINC3	APOBEC3G	Q9HC16	511
SERINC3	AP4E1	Q9UPM8	509
SERINC3	MX2	P20592	508
SERINC3	CCR5	P51681	503
SERINC3	CXCR4	P30991	474
SERINC3	ATG9A	Q7Z3C6	471
SERINC3	D6RGC4	D6RGC4	470

IntAct

30 interactions, top by confidence:

A	B	Type	Score
GRN	SERINC3	psi-mi:“MI:0915”(physical association)	0.560
SERINC3	PEX1	psi-mi:“MI:0915”(physical association)	0.560
SERINC3	WFS1	psi-mi:“MI:0915”(physical association)	0.560
SERINC3	TRIM28	psi-mi:“MI:0915”(physical association)	0.400
SERINC3	AGTR1	psi-mi:“MI:0915”(physical association)	0.370
SERINC3	DRD2	psi-mi:“MI:0915”(physical association)	0.370
SERINC3	RPS15	psi-mi:“MI:0915”(physical association)	0.370
SERINC3	BMP10	psi-mi:“MI:0915”(physical association)	0.370
Trappc8	TRAPPC13	psi-mi:“MI:0914”(association)	0.350
P2RY1	EI24	psi-mi:“MI:0914”(association)	0.350
CAPRIN1	VPS37C	psi-mi:“MI:0914”(association)	0.350
CAPRIN1	SDCBP	psi-mi:“MI:0914”(association)	0.350
EIF4A1	SNAP23	psi-mi:“MI:0914”(association)	0.350
SURF4	SERINC3	psi-mi:“MI:0915”(physical association)	0.000
SERINC3	KDELR1	psi-mi:“MI:0915”(physical association)	0.000
SERINC3	PHB2	psi-mi:“MI:0915”(physical association)	0.000
SERINC3	HACD3	psi-mi:“MI:0915”(physical association)	0.000
SERINC3	SLC16A1	psi-mi:“MI:0915”(physical association)	0.000
SERINC3	VDAC3	psi-mi:“MI:0915”(physical association)	0.000
SERINC3	KDELR2	psi-mi:“MI:0915”(physical association)	0.000
SERINC3	XPO5	psi-mi:“MI:0915”(physical association)	0.000
SERINC3	VDAC2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (23): SERINC3 (Affinity Capture-MS), XPO5 (Affinity Capture-MS), PHB2 (Affinity Capture-MS), SURF4 (Affinity Capture-MS), VDAC2 (Affinity Capture-MS), KDELR1 (Affinity Capture-MS), PTPLAD1 (Affinity Capture-MS), SLC16A1 (Affinity Capture-MS), KDELR2 (Affinity Capture-MS), SERINC3 (Proximity Label-MS), SERINC3 (Affinity Capture-MS), SERINC3 (Two-hybrid), SERINC3 (Two-hybrid), SERINC3 (Affinity Capture-MS), SERINC3 (Affinity Capture-RNA)

ESM2 similar proteins: A2VDC7, A4FUZ5, A9CAZ8, B9TRX0, O15243, O89013, O95807, P04116, P23289, P23294, P36963, P36965, P47789, P47790, P56557, P60201, P60202, P60203, Q0P442, Q0P467, Q13491, Q13530, Q1E1E0, Q3SYT0, Q3SZL9, Q3T110, Q3ZC23, Q4R6L9, Q561T9, Q566G2, Q5PSV5, Q5R4C3, Q5R533, Q5R603, Q5R6E6, Q5ZJD9, Q712P7, Q7TNK0, Q7Z0Q2, Q803X0

Diamond homologs: A4FUZ5, A6NH21, A7S4N4, A8WCG0, A9UY97, Q12116, Q13530, Q3MHV9, Q4R6L9, Q54UF8, Q58CW5, Q5R419, Q5R533, Q5XK03, Q63175, Q7TNK0, Q803X0, Q86VE9, Q8BHJ6, Q8K0E7, Q96SA4, Q9HDY3, Q9NRX5, Q9QZI8, Q9QZI9

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
CSNK2A1	“up-regulates activity”	SERINC3	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

90 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1637 predictions. Top by Δscore:

Variant	Effect	Δscore
20:44500430:CAGGG:C	acceptor_gain	1.0000
20:44500435:C:CC	acceptor_gain	1.0000
20:44501149:A:AC	donor_gain	1.0000
20:44501150:C:CC	donor_gain	1.0000
20:44501157:C:CA	donor_gain	1.0000
20:44501315:C:CT	acceptor_gain	1.0000
20:44501315:C:T	acceptor_gain	1.0000
20:44501316:A:T	acceptor_gain	1.0000
20:44503863:T:C	donor_gain	1.0000
20:44503883:A:AC	donor_gain	1.0000
20:44503884:C:CC	donor_gain	1.0000
20:44503884:CT:C	donor_gain	1.0000
20:44503992:CGAT:C	acceptor_gain	1.0000
20:44503994:ATCTG:A	acceptor_loss	1.0000
20:44503995:TC:T	acceptor_loss	1.0000
20:44503996:C:CC	acceptor_gain	1.0000
20:44503996:CTGAA:C	acceptor_loss	1.0000
20:44503997:T:G	acceptor_loss	1.0000
20:44509887:CTA:C	donor_loss	1.0000
20:44509888:TA:T	donor_loss	1.0000
20:44509890:C:CA	donor_loss	1.0000
20:44509890:CCAG:C	donor_gain	1.0000
20:44510024:CCAGA:C	acceptor_gain	1.0000
20:44510025:CAGA:C	acceptor_gain	1.0000
20:44510025:CAGAC:C	acceptor_gain	1.0000
20:44510026:AGA:A	acceptor_gain	1.0000
20:44510027:GA:G	acceptor_gain	1.0000
20:44510029:C:CC	acceptor_gain	1.0000
20:44512797:ATAC:A	donor_loss	1.0000
20:44512798:TA:T	donor_loss	1.0000

AlphaMissense

3112 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:44500368:G:C	S450R	0.996
20:44500368:G:T	S450R	0.996
20:44500370:T:G	S450R	0.996
20:44511353:T:A	K137N	0.996
20:44511353:T:G	K137N	0.996
20:44511364:A:G	W134R	0.996
20:44511364:A:T	W134R	0.996
20:44500367:A:G	W451R	0.995
20:44500367:A:T	W451R	0.995
20:44500343:A:G	W459R	0.994
20:44500343:A:T	W459R	0.994
20:44500302:G:C	F472L	0.992
20:44500302:G:T	F472L	0.992
20:44500304:A:G	F472L	0.992
20:44506846:G:C	S255W	0.992
20:44506868:A:G	C248R	0.992
20:44506884:A:C	S242R	0.992
20:44506884:A:T	S242R	0.992
20:44506886:T:G	S242R	0.992
20:44500330:G:T	A463D	0.991
20:44509991:G:C	F171L	0.991
20:44509991:G:T	F171L	0.991
20:44509993:A:G	F171L	0.991
20:44511354:T:A	K137I	0.991
20:44509956:G:T	A183D	0.990
20:44504818:G:T	A286D	0.989
20:44506878:G:C	N244K	0.989
20:44506878:G:T	N244K	0.989
20:44509977:A:G	L176P	0.989
20:44511355:T:C	K137E	0.989

dbSNP variants (sampled 300 via entrez): RS1000174768 (20:44513250 C>A), RS1000245326 (20:44523000 G>A), RS1000255314 (20:44508252 G>A,C), RS1000283629 (20:44517069 T>C), RS1000289603 (20:44504530 C>T), RS1000352638 (20:44501398 C>T), RS1000566066 (20:44512131 G>A), RS1000765317 (20:44503193 A>T), RS1000831035 (20:44501717 C>T), RS1000931522 (20:44496662 C>G,T), RS1001029847 (20:44505704 T>C), RS1001093133 (20:44502882 C>T), RS1001160868 (20:44499716 T>G), RS1001168940 (20:44521159 G>C,T), RS1001249045 (20:44517145 C>G)

Disease associations

OMIM: gene MIM:607165 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST000964_28	Ulcerative colitis	1.000000e-20
GCST001647_15	Bipolar disorder	9.000000e-06
GCST004131_41	Inflammatory bowel disease	1.000000e-17
GCST004133_4	Ulcerative colitis	4.000000e-30

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, affects expression, decreases expression	3
Ozone	affects cotreatment, increases oxidation, increases abundance, affects expression	2
FR900359	decreases phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
glycidyl methacrylate	increases expression	1
sodium arsenite	increases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, increases oxidation	1
K 7174	increases expression	1
Acetaminophen	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Asbestos	affects expression	1
Caffeine	increases phosphorylation	1
Dexamethasone	increases expression, affects cotreatment	1
Doxorubicin	decreases expression	1
Formaldehyde	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Lead	affects expression	1
Nicotine	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	increases expression	1
Vitamin E	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Sodium Selenite	increases expression	1
Particulate Matter	increases abundance, decreases expression	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.